Browse GPC2

Summary
SymbolGPC2
Nameglypican 2
Aliases cerebroglycan; FLJ38962; DKFZp547M109; glypican proteoglycan 2, cerebroglycan proteoglycan; glypican 2 (cere ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Lipid-anchor, GPI-anchor Extracellular side ; SUBCELLULAR LOCATION: Secreted glypican-2: Secreted, extracellular space
Domain PF01153 Glypican
Function

Cell surface proteoglycan that bears heparan sulfate. May fulfill a function related to the motile behaviors of developing neurons (By similarity).

> Gene Ontology
 
Biological Process GO:0001523 retinoid metabolic process
GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006026 aminoglycan catabolic process
GO:0006027 glycosaminoglycan catabolic process
GO:0006720 isoprenoid metabolic process
GO:0006721 terpenoid metabolic process
GO:0007224 smoothened signaling pathway
GO:0016101 diterpenoid metabolic process
GO:0030203 glycosaminoglycan metabolic process
GO:1901136 carbohydrate derivative catabolic process
GO:1901565 organonitrogen compound catabolic process
Molecular Function GO:0001948 glycoprotein binding
GO:0043394 proteoglycan binding
GO:0043395 heparan sulfate proteoglycan binding
GO:1901681 sulfur compound binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005775 vacuolar lumen
GO:0005796 Golgi lumen
GO:0031225 anchored component of membrane
GO:0043202 lysosomal lumen
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1971475: A tetrasaccharide linker sequence is required for GAG synthesis
R-HSA-1793185: Chondroitin sulfate/dermatan sulfate metabolism
R-HSA-4420332: Defective B3GALT6 causes EDSP2 and SEMDJL1
R-HSA-3560801: Defective B3GAT3 causes JDSSDHD
R-HSA-3560783: Defective B4GALT7 causes EDS, progeroid type
R-HSA-3656253: Defective EXT1 causes exostoses 1, TRPS2 and CHDS
R-HSA-3656237: Defective EXT2 causes exostoses 2
R-HSA-1643685: Disease
R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism
R-HSA-3781865: Diseases of glycosylation
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-2022928: HS-GAG biosynthesis
R-HSA-2024096: HS-GAG degradation
R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-6806667: Metabolism of fat-soluble vitamins
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-975634: Retinoid metabolism and transport
R-HSA-162582: Signal Transduction
R-HSA-2187338: Visual phototransduction
Summary
SymbolGPC2
Nameglypican 2
Aliases cerebroglycan; FLJ38962; DKFZp547M109; glypican proteoglycan 2, cerebroglycan proteoglycan; glypican 2 (cere ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GPC2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between GPC2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28898695NeuroblastomaInhibit immunityWe confirm GPC2 to be highly expressed on most neuroblastomas, but not detectable at appreciable levels in normal childhood tissues. In addition, we demonstrate that GPC2 is required for neuroblastoma proliferation.
Summary
SymbolGPC2
Nameglypican 2
Aliases cerebroglycan; FLJ38962; DKFZp547M109; glypican proteoglycan 2, cerebroglycan proteoglycan; glypican 2 (cere ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GPC2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGPC2
Nameglypican 2
Aliases cerebroglycan; FLJ38962; DKFZp547M109; glypican proteoglycan 2, cerebroglycan proteoglycan; glypican 2 (cere ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GPC2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.0770.0307
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.3810.157
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8720.367
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4410.371
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0890.956
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.1080.589
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4730.399
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5310.548
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2210.798
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3460.671
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.180.269
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5250.00436
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GPC2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolGPC2
Nameglypican 2
Aliases cerebroglycan; FLJ38962; DKFZp547M109; glypican proteoglycan 2, cerebroglycan proteoglycan; glypican 2 (cere ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GPC2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGPC2
Nameglypican 2
Aliases cerebroglycan; FLJ38962; DKFZp547M109; glypican proteoglycan 2, cerebroglycan proteoglycan; glypican 2 (cere ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GPC2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GPC2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGPC2
Nameglypican 2
Aliases cerebroglycan; FLJ38962; DKFZp547M109; glypican proteoglycan 2, cerebroglycan proteoglycan; glypican 2 (cere ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GPC2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGPC2
Nameglypican 2
Aliases cerebroglycan; FLJ38962; DKFZp547M109; glypican proteoglycan 2, cerebroglycan proteoglycan; glypican 2 (cere ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GPC2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGPC2
Nameglypican 2
Aliases cerebroglycan; FLJ38962; DKFZp547M109; glypican proteoglycan 2, cerebroglycan proteoglycan; glypican 2 (cere ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GPC2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGPC2
Nameglypican 2
Aliases cerebroglycan; FLJ38962; DKFZp547M109; glypican proteoglycan 2, cerebroglycan proteoglycan; glypican 2 (cere ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GPC2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.